B of A Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $50
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
B of A Securities analyst Alec Stranahan maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $50.
B of A Securities analyst Alec Stranahan maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $46 to $50.